Gamida Cell Ltd (fka GMDAQ)

[midastouch017]

RBC Capital Thinks Gamida Cell’s Stock is Going to Recover

November 23 2021 - 04:11AM

RBC Capital analyst Gregory Renza maintained a Buy rating on Gamida Cell (GMDA – Research Report) on November 15 and set a price target of $10.00. The company's shares closed last Monday at $2.78, close to its 52-week low of $2.75. According to TipRanks.com, Renza is a 1-star analyst with an average return of -1.1% and a 30.3% success rate. Renza covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Verrica Pharmaceuticals, and Inovio Pharmaceuticals. Currently, the analyst consensus on Gamida Cell is a Strong Buy with an average price target of $14.50, which is a 389.9% upside from current levels.

https://www.tipranks.com/news/blurbs/rbc-capital-thinks-gamida-cells-stock-is-going-to-recover?utm_source=advfn.com&utm_medium=referral